PD-1/PD-L1 Inhibitors May Improve Survival in NPC - Top-Institutions - MDSpire

PD-1/PD-L1 Inhibitors May Improve Survival in NPC

Meta-analysis suggests survival and response benefits alongside notable toxicity in recurrent or metastatic disease

  • By

  • Andrea Surnit

  • April 22, 2026

  • 2 min

Share

Top Institutions in Otolaryngology

Brief introduction explaining scope and methodology.

  • #1

    Sun Yat-sen University Cancer Center
    Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong

    Key Differentiators

    • Oncology
    • Head and Neck Cancer
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Head and Neck Cancer

  • #3

    National Cancer Center (NCC), Japan
    National Cancer Center (NCC), Japan

    Tokyo, Tokyo

    Key Differentiators

    • Oncology
    • Immunotherapy
    • Head and Neck Cancer

  • #4

    Shengjing Hospital of China Medical University
    Shengjing Hospital of China Medical University

    Shenyang, Liaoning

    Key Differentiators

    • Oncology
    • Head and Neck Cancer
    • Immunotherapy

Original Source(s)

PD-1/PD-L1 Inhibitors May Improve Survival in NPC

  • by Andrea Surnit

  • April 22, 2026

Related Content

Marriage as a Marker of Cancer Risk?

Never-married adults show markedly higher cancer incidence. A large population study asks why marital status remains a footnote in risk frameworks.

A safer airway strategy during induction and emergence: laryngeal mask airway versus face mask in pediatric rigid bronchoscopy

MDA5-related juvenile dermatomyositis and interstitial lung disease: Transitioning from rapid progression to a quiescent state in three pediatric cases from South Africa, along with a literature review.